The global antibiotic resistance market size was valued at USD 7.81 billion in 2017. It is anticipated to register a CAGR of 5.6% from 2018 to 2025. High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market.
Pharmaceutical companies, such as GlaxoSmithKline, Johnson & Johnson, Novartis, and Sanofi, are at the forefront of the global pharmaceutical industry but are less actively involved in clinical development of antibiotics. Majority of large pharmaceutical companies find the market lucrative enough due to relatively slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently canceled all plans to continue with R&D for its antibacterial drugs.
On the other hand, there are several biotech companies including Melinta Therapeutics, Achaogen, and Nabriva Therapeutics that have undertaken the challenge of developing therapies for antibiotic resistance. Involvement of international organizations serves as a catalyst in developed markets. Funding bodies such as BARDA are supporting biotech companies with financial support to complete early stage development of their novel therapies for antibiotic resistant infections.
Manufacturers seek the Qualified Infectious Disease Product (QIDP) designation, which expedites the clinical review process and extends exclusivity period for new generation antibiotics of strong therapeutic value. The QIDP designation was introduced under the Generating Antibiotic Incentives Now (GAIN) Act, passed in 2012 as an extension to the U.S. Food and Drug Administration Safety and Innovation Act. The legislation aims to promote the development of new therapies for growing burden and severity of antibiotic-resistant infections.
Based on disease type, the market has been categorized into cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, and CABP. cUTI represented the largest segment in the market in 2017 owing to high overall treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for majority of infection cases. Lack of low-cost treatment options for Gram-negative infections limits access to recently approved branded therapies such as Allergan’s Avycaz, Merck’s Zerbaxa, and Melinta Therapeutics’ Vabomere.
Antibiotic-resistant Gram-positive bacteria account for a larger number of infections by volume. However, due to availability of multiple treatment options including branded and generics drugs, the overall cost of therapy remains lower when compared with Gram-negative infections. Among gram-positive infections, MRSA accounted for the highest market share, being the primary causative pathogen for growing ABSSSI burden across the globe. The ABSSSI segment is projected to command a sizeable share in the antibiotic resistance market throughout the forecast period.
Infections due to K. pneumoniae pathogens that are carbapenem-resistant and ESBL-producing held the largest share in 2017. These infections pose treatment challenges for physicians due to high resistance to current treatment alternatives. These infections although fewer in terms of number of cases in comparison to Gram positive pathogens, they impose a high cost burden as physicians are increasingly shifting towards novel antibiotics such as Allergan’s Avycaz and Melinta Therapeutics’ Vabomere. CDI, on the other hand, is anticipated to register the highest CAGR during the forecast period.
Based on drug class, the market has been segmented into oxazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and others, which includes miscellaneous drug classes. Lipoglycopeptides are likely to command 17.0% of the overall market revenue by 2025.
The combination therapies segment, which comprises fixed dose combinations of beta lactams and beta lactamase inhibitors, is poised to experience the highest growth during the forecast period. High use of these therapies for gram negative infections that have limited treatment options is contributing to the growth of the segment.
North America was the largest region in terms of revenue in 2017. Numerous drug launches in the market and high treatment cost are supplementing the growth of the regional market. The U.S. will be a key revenue contributor in the region during the forecast period as guidelines, such as those defined by IDSA for the treatment of CDI, are promoting the use of novel therapies.
Europe was the second largest regional market in the global arena in 2017, supported largely by growing number of antibiotic-resistant infections. Among the OECD countries, Greece, Italy, and Portugal were ranked as the top 3 consumers of antibiotics in the world, contributing to increased antibiotic resistance in the region.
Some of the key players in the market are Pfizer, Merck, Allergan, and Melinta Therapeutics. This market has fewer pharmaceutical companies entering the space, while the number of biotech companies such as Achaogen and Nabriva Therapeutics is higher.
Large pharmaceutical companies are acquiring smaller entrants with novel antibiotics. The trend is expected to shape the future of the market. For instance, Pfizer acquired Astra Zeneca’s marketed drugs, Zavicefta and Zinforo, and late stage antibiotics, ATM-AVI, resulting in an expanded portfolio of antibiotics. In addition, companies in the market target for higher market share through indication extension and geographic expansion strategies.
Base year for estimation
2018 - 2025
Revenue in USD Billion and CAGR from 2014 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East and Africa
U.S., Canada, U.K., Germany, Italy, France, Spain, Belgium, Greece, Portugal, China, Japan, India, Hong Kong, Singapore, Australia, Argentina, Mexico, Brazil, Saudi Arabia, U.A.E., and South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global antibiotic resistance market report based on disease, pathogen, drugs class, and region:
Disease Outlook (Revenue, USD Billion, 2014 - 2025)
Complicated Urinary Tract Infection (cUTI)
Complicated Intra-Abdominal Infections (cIAI)
Blood Stream Infections (BSI)
Clostridium difficile infections (CDI)
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Pathogen Outlook (Revenue, USD Billion, 2014 - 2025)
Acinetobacter baumannii (Carbapenem-Resistant and ESBL-producing)
Pseudomonas aeruginosa (Carbapenem-Resistant)
Staphylococcus Aureus (Methicillin-Resistant)
E. coli/K. pneumoniae (Carbapenem-Resistant)
Streptococcus pneumoniae (Penicillin-Non-Susceptible)
Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
Enterococcus faecium (Vancomycin-Resistant)
Haemophilus Influenzae (Ampicillin-Resistant)
Drug Class Outlook (Revenue, USD Billion, 2014 - 2025)
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East and Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.